Teva Pharm Financials

TEVA

Export CSV

Key Financial Metrics

Revenue

$17.3B

YoY+4.3%

5Y CAGR+0.7%

10Y CAGR-1.3%

Teva Pharm generated $17.3B in revenue in fiscal year 2025. This represents an increase of 4.3% from the prior year.

EBITDA

$3.2B

YoY+317.9%

10Y CAGR-3.8%

Teva Pharm's EBITDA was $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 317.9% from the prior year.

Free Cash Flow

$1.1B

YoY+53.3%

5Y CAGR+12.5%

10Y CAGR-13.3%

Teva Pharm generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capital expenditures. This represents an increase of 53.3% from the prior year.

Net Income

$1.4B

YoY+186.0%

10Y CAGR-1.2%

Teva Pharm reported $1.4B in net income in fiscal year 2025. This represents an increase of 186.0% from the prior year.

EPS (Diluted)

$1.21

YoY+183.4%

10Y CAGR-4.0%

Teva Pharm earned $1.21 per diluted share in fiscal year 2025. This represents an increase of 183.4% from the prior year.

Cash & Debt

$3.6B

YoY+7.8%

5Y CAGR+10.3%

10Y CAGR-6.5%

Teva Pharm held $3.6B in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

1.15B

YoY+1.4%

5Y CAGR+1.0%

10Y CAGR+1.2%

Teva Pharm had 1.15B shares outstanding in fiscal year 2025. This represents an increase of 1.4% from the prior year.

Gross Margin

51.8%

YoY+3.1pp

5Y CAGR+5.4pp

10Y CAGR-6.0pp

Teva Pharm's gross margin was 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.

Operating Margin

12.5%

YoY+14.3pp

5Y CAGR+33.9pp

10Y CAGR-4.6pp

Teva Pharm's operating margin was 12.5% in fiscal year 2025, reflecting core business profitability. This is up 14.3 percentage points from the prior year.

Net Margin

8.2%

YoY+18.1pp

5Y CAGR+32.1pp

10Y CAGR+0.1pp

Teva Pharm's net profit margin was 8.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 18.1 percentage points from the prior year.

Return on Equity

17.8%

10Y CAGR+12.5pp

Teva Pharm's return on equity was 17.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

R&D Spending

$1.0B

YoY+1.5%

5Y CAGR+0.3%

10Y CAGR+40.0%

Teva Pharm invested $1.0B in research and development in fiscal year 2025. This represents an increase of 1.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$501.0M

YoY+0.6%

5Y CAGR-2.8%

10Y CAGR-4.2%

Teva Pharm invested $501.0M in capital expenditures in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.6% from the prior year.

TEVA Income Statement

Metric	FY25	FY25	FY25	FY24	FY23	FY22
Revenue	$17.3B+4.3%	$16.5B+4.4%	$15.8B+6.2%	$14.9B-6.0%	$15.9B-4.7%	$16.7B
Cost of Revenue	$8.3B-1.9%	$8.5B+3.4%	$8.2B+3.1%	$8.0B-4.0%	$8.3B-7.3%	$8.9B
Gross Profit	$8.9B+10.8%	$8.1B+5.5%	$7.6B+9.6%	$7.0B-8.2%	$7.6B-1.7%	$7.7B
R&D Expenses	$1.0B+1.5%	$998.0M+4.7%	$953.0M+13.7%	$838.0M-13.3%	$967.0M-3.0%	$997.0M
SG&A Expenses	$1.3B+10.9%	$1.2B-0.1%	$1.2B-1.5%	$1.2B+7.4%	$1.1B-6.3%	$1.2B
Operating Income	$2.2B+811.9%	-$303.0M-170.0%	$433.0M+119.7%	-$2.2B-228.0%	$1.7B+148.0%	-$3.6B
Interest Expense	$916.0M-8.6%	$1.0B-2.6%	$1.0B+10.6%	$930.0M+4.4%	$891.0M-1.1%	$901.0M
Income Tax	-$180.0M-126.6%	$676.0M+9757.1%	-$7.0M+98.9%	-$643.0M-404.7%	$211.0M+225.6%	-$168.0M
Net Income	$1.4B+186.0%	-$1.6B-193.2%	-$559.0M+77.1%	-$2.4B-686.6%	$417.0M+110.5%	-$4.0B
EPS (Diluted)	$1.21+183.4%	$-1.45-190.0%	$-0.50+77.3%	$-2.20-678.9%	$0.38+110.4%	$-3.64

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$1.5B-66.5%	$4.5B+7.3%	$4.2B+7.3%	$3.9B	N/A	$4.3B+4.0%	$4.2B+9.0%	$3.8B
Cost of Revenue	N/A	$2.2B+4.9%	$2.1B+3.0%	$2.0B	N/A	$2.2B+2.0%	$2.1B+4.5%	$2.0B
Gross Profit	N/A	$2.3B+9.6%	$2.1B+12.0%	$1.9B	N/A	$2.1B+6.1%	$2.0B+14.3%	$1.8B
R&D Expenses	N/A	$256.0M+4.9%	$244.0M-1.2%	$247.0M	N/A	$240.0M-10.8%	$269.0M+11.2%	$242.0M
SG&A Expenses	N/A	$317.0M+3.9%	$305.0M+2.7%	$297.0M	N/A	$298.0M+5.3%	$283.0M+1.8%	$278.0M
Operating Income	N/A	$882.0M+93.8%	$455.0M-12.3%	$519.0M	N/A	-$51.0M-920.0%	-$5.0M+97.7%	-$218.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$214.0M+374.4%	-$78.0M-205.4%	$74.0M	N/A	$69.0M-89.0%	$630.0M+1311.5%	-$52.0M
Net Income	N/A	$433.0M+53.5%	$282.0M+31.8%	$214.0M	N/A	-$437.0M+48.3%	-$846.0M-508.6%	-$139.0M
EPS (Diluted)	N/A	$0.37+54.2%	$0.24+33.3%	$0.18	N/A	$-0.39+48.0%	$-0.75-525.0%	$-0.12

TEVA Balance Sheet

Metric	FY25	FY25	FY25	FY24	FY23	FY22
Total Assets	$40.7B+3.6%	$39.3B-9.6%	$43.5B-1.2%	$44.0B-7.7%	$47.7B-5.9%	$50.6B
Current Assets	$13.9B+11.1%	$12.6B+0.5%	$12.5B+3.6%	$12.1B-4.2%	$12.6B-3.3%	$13.0B
Cash & Equivalents	$3.6B+7.8%	$3.3B+2.3%	$3.2B+15.2%	$2.8B+29.4%	$2.2B-0.6%	$2.2B
Inventory	$3.2B+5.7%	$3.0B-25.2%	$4.0B+4.9%	$3.8B+0.4%	$3.8B-13.3%	$4.4B
Accounts Receivable	$3.7B+21.2%	$3.1B-10.2%	$3.4B-7.8%	$3.7B-18.4%	$4.5B-1.1%	$4.6B
Goodwill	$16.0B+5.6%	$15.1B-11.8%	$17.2B0.0%	$17.2B-2.6%	$17.6B-14.5%	$20.6B
Total Liabilities	$32.8B-2.3%	$33.6B-4.9%	$35.4B-0.2%	$35.4B-2.8%	$36.4B-8.0%	$39.6B
Current Liabilities	$13.5B+5.2%	$12.8B+4.5%	$12.2B+6.8%	$11.5B+4.0%	$11.0B-16.2%	$13.2B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.9B+47.2%	$5.4B-33.9%	$8.1B-5.5%	$8.6B-23.5%	$11.2B+1.7%	$11.1B
Retained Earnings	-$13.8B+9.3%	-$15.2B-12.1%	-$13.5B-4.3%	-$13.0B-23.2%	-$10.5B+3.8%	-$10.9B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$40.7B+2.2%	$39.9B-0.7%	$40.1B+4.5%	$38.4B-2.3%	$39.3B-5.8%	$41.8B+1.0%	$41.3B-3.4%	$42.8B
Current Assets	$13.9B+9.5%	$12.7B+0.9%	$12.6B+9.5%	$11.5B-8.2%	$12.6B+1.9%	$12.3B+5.9%	$11.6B-5.4%	$12.3B
Cash & Equivalents	$3.6B+61.4%	$2.2B+1.9%	$2.2B+27.3%	$1.7B-48.6%	$3.3B-0.6%	$3.3B+47.0%	$2.3B-24.5%	$3.0B
Inventory	$3.2B-4.3%	$3.3B-5.0%	$3.5B+7.7%	$3.2B+8.0%	$3.0B-24.0%	$4.0B+0.8%	$3.9B-0.6%	$3.9B
Accounts Receivable	$3.7B-2.7%	$3.8B+6.9%	$3.6B+5.3%	$3.4B+10.6%	$3.1B-11.6%	$3.5B-8.1%	$3.8B+9.0%	$3.5B
Goodwill	$16.0B+0.3%	$15.9B0.0%	$15.9B+3.0%	$15.5B+2.2%	$15.1B-6.1%	$16.1B-2.2%	$16.5B-3.1%	$17.0B
Total Liabilities	$32.8B+0.7%	$32.6B-2.1%	$33.3B+3.6%	$32.1B-4.3%	$33.6B-5.0%	$35.4B+1.7%	$34.8B-1.3%	$35.2B
Current Liabilities	$13.5B+17.1%	$11.5B-3.1%	$11.9B+6.3%	$11.2B-12.8%	$12.8B-7.3%	$13.8B+5.8%	$13.0B-5.5%	$13.8B
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.9B+9.1%	$7.3B+6.1%	$6.8B+9.0%	$6.3B+16.7%	$5.4B-15.8%	$6.4B-2.7%	$6.6B-13.0%	$7.5B
Retained Earnings	-$13.8B+3.4%	-$14.2B+3.0%	-$14.7B+1.9%	-$15.0B+1.4%	-$15.2B-1.5%	-$15.0B-3.0%	-$14.5B-6.2%	-$13.7B

TEVA Cash Flow Statement

Metric	FY25	FY25	FY25	FY24	FY23	FY22
Operating Cash Flow	$1.6B+32.2%	$1.2B-8.8%	$1.4B-14.0%	$1.6B+99.2%	$798.0M-34.4%	$1.2B
Capital Expenditures	$501.0M+0.6%	$498.0M-5.3%	$526.0M-4.0%	$548.0M-2.5%	$562.0M-2.8%	$578.0M
Free Cash Flow	$1.1B+53.3%	$749.0M-11.0%	$842.0M-19.2%	$1.0B+341.5%	$236.0M-63.0%	$638.0M
Investing Cash Flow	$737.0M-6.9%	$792.0M-18.2%	$968.0M+47.6%	$656.0M-56.9%	$1.5B+76.5%	$863.0M
Financing Cash Flow	-$2.2B-20.1%	-$1.8B+6.4%	-$1.9B-28.6%	-$1.5B+31.5%	-$2.2B-15.2%	-$1.9B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	N/A	$369.0M+62.6%	$227.0M+316.2%	-$105.0M	N/A	$693.0M+572.8%	$103.0M+183.1%	-$124.0M
Capital Expenditures	N/A	$136.0M+41.7%	$96.0M-24.4%	$127.0M	N/A	$148.0M+52.6%	$97.0M-21.8%	$124.0M
Free Cash Flow	N/A	$233.0M+77.9%	$131.0M+156.5%	-$232.0M	N/A	$545.0M+8983.3%	$6.0M+102.4%	-$248.0M
Investing Cash Flow	N/A	$135.0M-42.8%	$236.0M+17.4%	$201.0M	N/A	$268.0M+50.6%	$178.0M+23.6%	$144.0M
Financing Cash Flow	N/A	-$453.0M-7650.0%	$6.0M+100.3%	-$1.7B	N/A	$0+100.0%	-$966.0M-539.7%	-$151.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TEVA Financial Ratios

Metric	FY25	FY25	FY25	FY24	FY23	FY22
Gross Margin	51.8%+3.1pp	48.7%+0.5pp	48.3%+1.5pp	46.7%-1.1pp	47.8%+1.5pp	46.4%
Operating Margin	12.5%+14.3pp	-1.8%-4.6pp	2.7%+17.4pp	-14.7%-25.5pp	10.8%+32.3pp	-21.4%
Net Margin	8.2%+18.1pp	-9.9%-6.4pp	-3.5%+12.9pp	-16.4%-19.0pp	2.6%+26.6pp	-23.9%
Return on Equity	17.8%	N/A	N/A	N/A	3.7%	N/A
Return on Assets	3.5%+7.6pp	-4.2%-2.9pp	-1.3%+4.3pp	-5.6%-6.4pp	0.9%+8.8pp	-7.9%
Current Ratio	1.04+0.1	0.98-0.0	1.02-0.0	1.05-0.1	1.14+0.2	0.99
Debt-to-Equity	4.15-2.1	6.25+1.9	4.35+0.2	4.12+0.9	3.24-0.3	3.58
FCF Margin	6.7%+2.1pp	4.5%-0.8pp	5.3%-1.7pp	7.0%+5.5pp	1.5%-2.3pp	3.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	N/A	51.4%+1.1pp	50.3%+2.1pp	48.2%	N/A	49.6%+1.0pp	48.6%+2.2pp	46.4%
Operating Margin	N/A	19.7%+8.8pp	10.9%-2.4pp	13.3%	N/A	-1.2%-1.1pp	-0.1%+5.6pp	-5.7%
Net Margin	N/A	9.7%+2.9pp	6.8%+1.3pp	5.5%	N/A	-10.1%+10.2pp	-20.3%-16.7pp	-3.6%
Return on Equity	N/A	6.0%+1.8pp	4.1%+0.7pp	3.4%	N/A	N/A	N/A	N/A
Return on Assets	N/A	1.1%+0.4pp	0.7%+0.1pp	0.6%	N/A	-1.1%+1.0pp	-2.1%-1.7pp	-0.3%
Current Ratio	1.04-0.1	1.11+0.0	1.06+0.0	1.03+0.1	0.98+0.1	0.890.0	0.890.0	0.89
Debt-to-Equity	4.15-0.3	4.50-0.4	4.87-0.3	5.13-1.1	6.25+0.7	5.54+0.2	5.30+0.6	4.67
FCF Margin	N/A	5.2%+2.1pp	3.1%+9.1pp	-6.0%	N/A	12.6%+12.4pp	0.1%+6.6pp	-6.5%

Frequently Asked Questions

What is Teva Pharm's annual revenue?

Teva Pharm (TEVA) reported $17.3B in revenue for fiscal year 2025.

How fast is Teva Pharm's revenue growing?

Teva Pharm (TEVA) revenue grew by 4.3% year-over-year, from $16.5B to $17.3B in fiscal year 2025.

Is Teva Pharm profitable?

Yes, Teva Pharm (TEVA) reported a net income of $1.4B in fiscal year 2025, with a net profit margin of 8.2%.

What is Teva Pharm's earnings per share (EPS)?

Teva Pharm (TEVA) reported diluted earnings per share of $1.21 for fiscal year 2025.

What is Teva Pharm's EBITDA?

Teva Pharm (TEVA) had EBITDA of $3.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Teva Pharm's gross margin?

Teva Pharm (TEVA) had a gross margin of 51.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Teva Pharm's operating margin?

Teva Pharm (TEVA) had an operating margin of 12.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Teva Pharm's net profit margin?

Teva Pharm (TEVA) had a net profit margin of 8.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Teva Pharm's return on equity (ROE)?

Teva Pharm (TEVA) has a return on equity of 17.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Teva Pharm's free cash flow?

Teva Pharm (TEVA) generated $1.1B in free cash flow during fiscal year 2025, representing cash available after capital expenditures.

What is Teva Pharm's operating cash flow?

Teva Pharm (TEVA) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Teva Pharm's total assets?

Teva Pharm (TEVA) had $40.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Teva Pharm's capital expenditures?

Teva Pharm (TEVA) invested $501.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Teva Pharm spend on research and development?

Teva Pharm (TEVA) invested $1.0B in research and development during fiscal year 2025.

How many shares does Teva Pharm have outstanding?

Teva Pharm (TEVA) had 1.15B shares outstanding as of fiscal year 2025.

What is Teva Pharm's current ratio?

Teva Pharm (TEVA) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.

What is Teva Pharm's debt-to-equity ratio?

Teva Pharm (TEVA) had a debt-to-equity ratio of 4.15 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Teva Pharm's return on assets (ROA)?

Teva Pharm (TEVA) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.